Full Text View
Tabular View
No Study Results Posted
Related Studies
Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
This study has been completed.
Study NCT00093782   Information provided by National Cancer Institute (NCI)

First Received on October 6, 2004.   Last Updated on May 7, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Pulmonary Carcinoid Tumor
Recurrent Islet Cell Carcinoma
Additional conditions recognized in this trial
Carcinoid Tumor
Carcinoma
Carcinoma, Islet Cell
Carcinoma, Neuroendocrine
Gastrointestinal Neoplasms
Malignant Carcinoid Syndrome
More general conditions related to this trial
Adenocarcinoma
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Gastrointestinal Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Pancreatic Diseases
Pancreatic Neoplasms
Interventions listed in this trial
temsirolimus
laboratory biomarker analysis
Additional drug interventions recognized in this trial
Everolimus
Sirolimus
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services